{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'human', 'teratogenicity/genotoxicity/fetoto', 'xicity. Conduct monthly', 'pregnancy testing and in case the', 'IMP has a marketing', 'authorization, if the IMP has a', 'demonstrated or suspected human', 'eratogenicity/genotoxicity/fetoto', 'xicity according to Risk Safety', 'Information. Shorter testing', 'intervals are to be considered', 'depending on drug dosing', 'schedule.', '2. Consider additional pregnancy', 'testing, but at least at the end of', 'relevant systemic exposure, in', 'case of possible human', 'teratogenicity/fetotoxicity. This', 'refers to IMPs, for which human', 'data on pregnancies is limited or', 'not available, there is no', 'suspicion of human teratogenicity', 'based on class effects or', 'genotoxic potential, and', 'nonclinical reproductive toxicity', 'studies of relevance for early', 'human pregnancy show positive', 'findings that do not generate a', 'strong suspicion of human', 'teratogenicity/ fetotoxicity.', '3. For IMPs with unlikely risk of', 'human', 'teratogenicity/fetotoxicity', 'additional pregnancy testing is', 'generally not necessary. This', 'refers to IMPs for which', 'assessment of the completed', 'necessary nonclinical studies', 'does not indicate teratogenicity/', 'fetotoxicity in early pregnancy', 'and human data are not available', 'or do not contradict these', 'findings or there is already', 'sufficient evidence for lack of', 'risk based on human data.', 'Pregnant female partners of male', '134']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'study participants:', 'Male study participants must use', 'condoms during intercourse if their', 'female partners are pregnant.', '135']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '17.2.', 'Amendment 02 Dated 03 October 2017', 'The primary reason for this amendment is to incorporate CYP2D6 genotyping results into the', 'IRT in order to allow for a dose cap to be applied in a blinded manner, update drug packaging to', 'ensure blinding of CYP2D6 impairment status, reorder the statistical testing methodology (ie, the', 'inclusion of TS-PGII assessment after TS-CGI and before the C&A-GTS-QOL ADL subscale),', 'clarify the study day window for each visit or call, and include prohibited medications that are', 'associated with QTc prolongation.', 'This amendment is considered to be substantial (ie, requires approval by Competent Authority,', \"IEC, and/or IRB) by the sponsor's Authorized Representative. Other nonsubstantial changes\", 'have been made to the protocol (and protocol synopsis, as appropriate). These changes are', 'unlikely to affect the safety or rights (physical or mental integrity) of the patients in this clinical', 'study or the scientific value of the clinical study.', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'CLINICAL LABORATORY AND OTHER DEPARTMENTS AND INSTITUTIONS', 'Central Institutional Review Board', 'Copernicus Group IRB', 'Change to central', 'Quorum Review IRB', '1 Triangle Drive', 'IRB', '1501 Fourth Avenue, Suite 800', 'Durham, NC 27709', 'Seattle, WA 98101', 'USA', 'USA', 'Copernicus Group IRB', '1 Triangle Drive', 'Durham, NC 27709', 'USA', 'CLINICAL STUDY PERSONNEL CONTACT INFORMATION', 'For operational issues, contact the', 'For operational issues, contact the', 'Change in', 'operational lead listed below:', 'operational lead listed below:', 'Nuvelution study', 'personnel', 'For protocol issues, contact the study', 'leader listed below:', 'For protocol issues, contact the study', '136']\n\n###\n\n", "completion": "END"}